TGFB1 and neoplasm: Preclinical evidence demonstrated that TGF-β blockade combined with PD-L1 antibody can decrease TGF-β signal transduction in stromal cells, promote T cell infiltration to tumor center, induce the anti-tumor immune effect, and bring a tumor regression effect [41,42,43].